The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST-Reference-Cited by-同舟云学术

The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST

Published:2018-03 Issue:2 Volume:104 Page:88-95
ISSN:0300-8916
Container-title:Tumori Journal
language:en
Short-container-title:Tumori

Author:

Inno Alessandro¹,Lo Russo Giuseppe²,Salgarello Matteo³,Corrao Giulia²,Casolino Raffaella¹,Galli Giulia²,Modena Alessandra¹,Romano Luigi⁴,Pusceddu Sara²,Greco Francesca Gabriella⁵,Garassino Marina Chiara¹,Gori Stefania¹

Affiliation:

1. Unità di Oncologia Medica, Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy

2. Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

3. Unità di Medicina Nucleare, Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy

4. Unità di Radiologia, Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy

5. Unità di Radiologia Diagnostica e Interventistica, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Abstract

The objective response is an important endpoint to evaluate clinical activity of new anticancer drugs. Standardized criteria for evaluating response are needed for comparing results of different trials and represent the basis for advances in cancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 are the most used in clinical practice and in clinical trials; however, they are not able to capture atypical responses seen with immunotherapy drugs. We describe the evolution of response criteria with a special focus on the immune-related criteria.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/0300891618766173

Reference26 articles.

1. Meaningful clinical classification of therapeutic responses to anticancer drugs

2. Reporting results of cancer treatment

3. New Guidelines to Evaluate the Response to Treatment in Solid Tumors

4. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear medicine in therapy response monitoring in cancer treatment;Gazzetta Medica Italiana Archivio per le Scienze Mediche;2023-11

2. Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis;Diseases;2023-10-23

3. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer;World Journal of Gastrointestinal Surgery;2023-05-27

4. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma;Nature Reviews Urology;2022-11-21

5. Tumour invasion and dissemination;Biochemical Society Transactions;2022-06-17